drugset / Trial / NCT07433621
Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.
Timeline
- Start
- 2026-02-26
- Primary completion
- 2028-11
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quercetin | Small molecule | 4000 mg | Oral |